Articles related to GLP-1s

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

Rapid weight loss from semaglutide use can lead to breast ptosis, mirroring effects seen after bariatric surgery. Healthcare providers should be prepared to counsel patients on this potential outcome and offer strategies for management.

A diet high in soluble fiber, protein, and healthy fats can mimic the effects of GLP-1 agonists like Ozempic, offering a safer alternative for weight management and metabolic health.

GLP-1 receptor agonists, beyond their role in diabetes and obesity management, are showing promise in reducing alcohol cravings, potentially offering a novel approach to treating alcohol use disorder.

Patients on GLP-1 medications may experience notable changes in breast morphology, such as decreased volume and increased sagging. Medical experts recommend supportive measures and a stable weight before considering surgical interventions.

Ozempic, commonly used off-label for weight management, can cause significant facial side effects, termed “Ozempic face,” marked by increased wrinkling and loss of skin elasticity.